WHIPPANY, N.J.--(BUSINESS WIRE)--In honor of World Dense Breast Day on September 25, Bayer announced today a new study, published in Patient Preference and Adherence, evaluating awareness and knowledge gaps of breast cancer risk factors (BCRFs) among women with and without high breast density (HBD).

拜耳公司今天宣布了一项新的研究，该研究发表在《患者偏好和依从性》杂志上，以纪念9月25日的世界致密乳房日，该研究评估了有或没有高乳房密度（HBD）的女性对乳腺癌危险因素（BCRFs）的认识和知识差距。

The study, a web-based survey, found only 39 percent were familiar with the concept of HBD in the context of breast cancer, and 31 percent were aware of HBD as a Breast Cancer Risk Factor (BCRF). Three thousand women were surveyed from six different countries – the United States, Germany, Italy, South Korea, Brazil and Mexico (500 from each country).

这项基于网络的调查发现，只有39%的人在乳腺癌的背景下熟悉HBD的概念，31%的人知道HBD是乳腺癌的危险因素（BCRF）。来自美国、德国、意大利、韩国、巴西和墨西哥六个不同国家的3000名女性接受了调查（每个国家500名）。

The survey was supported by Bayer and conducted with Trinity Life Sciences in the U.S., University Medical Center Utrecht in the Netherlands and University Medical School of Saarland in Germany.1.

这项调查得到了拜耳公司的支持，并与美国三一生命科学公司、荷兰乌得勒支大学医学中心和德国萨尔大学医学院共同进行。

The new publication comes as an updated U.S. Food and Drug Administration (FDA) regulation, which went into effect earlier this month, now requires mammography facilities to provide patients with an overall assessment of their breast density as part of their mammography report. They must also inform patients that dense tissue makes it harder to find breast cancer on a mammogram and also increases the risk of developing breast cancer.

这份新出版物是美国食品和药物管理局（FDA）最新法规的一部分，该法规于本月早些时候生效，现在要求乳房X光检查设施为患者提供乳房密度的整体评估，作为其乳房X光检查报告的一部分。。

These facilities will also be required to inform patients with dense breasts that in some people with dense tissue, other imaging tests in addition to a mammogram may help find cancers.2.

。

HBD is one of the strongest independent and non-modifiable BCRFs. In fact, women with extremely dense breast tissue have a 4.6-fold increase in breast cancer risk compared to women with almost totally fatty breast tissue.3 The lack of awareness of BCRFs, which include but are not limited to, breast density, sex, age, family history, late first pregnancy, obesity, alcohol intake, smoking, low physical activity, and hormone replacement therapy, can contribute to delays in screenings, missed opportunities for early breast cancer detection and potentially lead to poorer health outcomes.4,5.

HBD是最强的独立且不可修改的BCRF之一。事实上，与几乎完全脂肪乳腺组织的女性相比，乳腺组织密度极高的女性患乳腺癌的风险增加了4.6倍[3]。缺乏对BCRFs的认识，包括但不限于乳腺密度，性别，年龄，家族史，首次妊娠晚期，肥胖，饮酒，吸烟，体力活动不足和激素替代疗法，可能导致筛查延迟，错过早期乳腺癌检测的机会，并可能导致较差的健康结果[4,5]。

“Breast cancer is the most frequently diagnosed cancer among women worldwide6 and it’s critical that patients have easy access to information about risk factors, including extremely dense breasts,” said Wagdy Youseff, Head of Medical Affairs, Radiology Americas. “Bayer is committed to investing in important initiatives like this assessment to help build awareness of the need for further patient education and encourage discussions with HCPs about breast cancer screenings and risk factors.”.

“乳腺癌是全世界女性中最常被诊断出的癌症6，至关重要的是患者能够轻松获得有关风险因素的信息，包括极度致密的乳房，”美国放射学医学事务负责人Wagdy Youseff说。“拜耳致力于投资于像本评估这样的重要举措，以帮助建立对进一步患者教育需求的认识，并鼓励与HCP讨论乳腺癌筛查和风险因素。”。

Given the majority of women polled in the study (63 percent) cited health care professionals (HCPs) as the most relevant source of information about breast cancer, increasing education among HCPs and their patients about BCRFs is a key factor for overall breast cancer awareness and improved screening participation.

鉴于在这项研究中接受调查的大多数女性（63%）认为医疗保健专业人员（HCP）是有关乳腺癌的最相关信息来源，因此增加HCP及其患者对BCRFs的教育是提高整体乳腺癌意识和改善筛查参与度的关键因素。

As breast cancer is one of the world's most commonly diagnosed cancer among women, educating patients about BCRFs, including breast density, may create opportunities for early detection.7.

由于乳腺癌是世界上女性中最常被诊断出的癌症之一，因此对患者进行有关BCRF（包括乳腺密度）的教育可能会为早期发现创造机会。

For more information about the study, please visit: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11298181/#cit0008.

有关该研究的更多信息，请访问：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11298181/#cit0008.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家全球性企业，在医疗保健和营养等生命科学领域拥有核心竞争力。根据其“人人健康，无人饥饿”的使命，该公司的产品和服务旨在通过支持应对全球人口不断增长和老龄化带来的重大挑战，帮助人们和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros.

拜耳致力于推动可持续发展，并对其业务产生积极影响。。拜耳品牌代表着全世界的信任、可靠性和质量。2023财年，该集团雇佣了约10万人，销售额476亿欧元。

R&D expenses before special items amounted to 5.8 billion euros..

特殊项目前的研发费用为58亿欧元。。

Find more information at https://pharma.bayer.com/

更多信息请访问https://pharma.bayer.com/

Follow us on Facebook: http://www.facebook.com/bayer

Follow us on Facebook: http://www.facebook.com/bayer

Follow us on X: @BayerPharma

在X上关注我们：@BayerPharma

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本版本可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司的实际未来业绩、财务状况、发展或业绩与此处给出的估计之间存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to confirm them to future events or developments..

这些因素包括拜耳网站www.Bayer.com上拜耳公开报告中讨论的因素。公司不承担任何责任更新这些前瞻性声明或根据未来事件或发展确认这些声明。。

_____________________________

_____________________________

1 Endrikat J, Schmidt G, Oak B, Shukla V, Nangia P, Schleyer N, Crocker J, Pijnapppel R. Awareness of Breast Cancer Risk Factors in Women with vs. Without High Breast Density. Patient Prefer Adherence. 2024 Jul 31;18:1577-1588. doi: 10.2147/PPA.S466992. PMID: 39100427; PMCID: PMC11298181.

1 Endrikat J，Schmidt G，Oak B，Shukla V，Nangia P，Schleyer N，Crocker J，Pijnapppel R.对乳腺癌危险因素的认识。患者更喜欢依从性。2024年7月31日；18： 1577-1588年。doi:10.2147/PPA。S466992。PMID:39100427；。

2 Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA). U.S. Food and Drug Administration. Updated September 10, 2024. Accessed September 17, 2024. https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa..

。U、 美国食品和药物管理局。2024年9月10日更新。2024年9月17日访问。https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa..

3 McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69. doi: 10.1158/1055-9965.EPI-06-0034. PMID: 16775176.

3 McCormack VA，dos Santos Silva I.乳腺密度和实质模式作为乳腺癌风险标志物：荟萃分析。癌症流行病学生物标志物。2006年6月；15（6）：1159年至1159年。doi:10.1158/1055-9965.EPI-06-0034。PMID:16775176。

4 Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287. PMID: 34503097; PMCID: PMC8428369..

4Łukasiewicz S，Czeczelewski M，Forma A，Baj J，Sitarz R，Stanisławek A.乳腺癌流行病学，危险因素，分类，预后标志物和当前治疗策略-最新综述。癌症（巴塞尔）。2021年8月25日；13（17）：4287。doi:10.3390/癌症13174287。PMID:34503097；PMCID:PMC8428369。。

5 Breast Cancer Treatment (PDQ)–Patient Version. National Cancer Institute. Updated: August 23, 2024. Accessed September 17, 2024. https://www.cancer.gov/types/breast/patient/breast-treatment-pdq#_125www.cancer.gov/types/breast/patient/breast-treatment-pdq.

5乳腺癌治疗（PDQ）-患者版本。国家癌症研究所。更新日期：2024年8月23日。2024年9月17日访问。https://www.cancer.gov/types/breast/patient/breast-treatment-pdq#_125www.cancer.gov/types/breast/patient/breast-。

6 Breast cancer statistics. World Cancer Research Fund International. Accessed September 23, 2024. https://www.wcrf.org/cancer-trends/breast-cancer-statistics/#:~:text=Breast%20cancer%20is%20the%202nd,number%20one%20cancer%20in%20women.

6乳腺癌统计。世界癌症研究基金会国际。。https://www.wcrf.org/cancer-trends/breast-cancer-statistics/#:~：text=乳腺癌是第二位，女性中有一位患有癌症。

7 Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022; 128(24): 4251-4284. doi:10.1002/cncr.34479.

7 Cronin KA，Scott S，Firth AU等人，《国家癌症状况年度报告》，第1部分：国家癌症统计。癌症。2022年；128（24）：4251-4284。doi:10.1002/cncr.34479。

PP-PF-RAD-US-1199 September 2024

PP-PF-RAD-US-1199 2024年9月